About: A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer
Creator	Abrahamyan, Levon Kleiman, Lawrence Bouvier, Michel Clément, Jean-Francois Hu, Kimberly Strebel, Klaus Mouland, Andrew
source	Elsevier; Medline; PMC
abstract	A sensitive reporter assay to measure human immunodeficiency virus type 1 (HIV-1) protease (PR) activity is described in this manuscript. This assay measures PR activity as a function of the resonance energy transfer (RET) between a donour molecule [humanized sea pansy Renilla reniformis luciferase (hRLuc)] and an energy acceptor molecule, humanized green fluorescent protein (hGFP2) when expressed in mammalian cells. This is a naturally occurring phenomenon and is an emerging and powerful technology that has significant advantages over alternative in vitro PR assays. The HIV-1 Gag-p2/Gag-p7 (p2/p7) PR site was inserted between hGFP2 and hRLuc. The newly created vector, hRLuc-p2/p7-hGFP2 was co-expressed with an HIV-1 codon-optimized PR+ or PR− Gag/Pol expressor. Expression of the hRLuc-p2/p7-hGFP2 alone or with the PR− Gag-Pol expressor generated a BRET2 indicating that the PR cleavage site was not cleaved, whereas the inclusion of the PR+ Gag-Pol produced a significant reduction in the BRET2. The inclusion of PR inhibitors Saquinavir or Amprenavir, or the expression of a p2/p7 PR substrate mutant also blocked the cleavage to result in a stable BRET2 signal. Because the HIV-1 auxiliary protein Vif has been shown to modulate the HIV-1 p2/p7 cleavage, this assay was then validated in studies in which Vif was expressed. When Vif was overexpressed along with hRLuc-p2/p7-hGFP2 and PR+ Gag-Pol, the decrease in BRET2 was abrogated in a dose-dependent manner, demonstrating that supraphysiologic levels of Vif block p2/p7 cleavage. An accumulation of a Gag processing intermediate was observed, indicating that p2/p7 cleavage was negatively affected. Overexpression of an RNA-binding-defective Staufen protein or a related dsRNA-binding protein TRBP had no effect on PR cleavage activity as shown by Western and BRET2 analyses. The p2/p7 processing data were confirmed by Western blot analyses. BRET is non-invasive and occurs within live cells, is measured in real time, and is not restricted to cellular compartments making it an especially attractive technology to identify small bioactive inhibitory molecules. This PR BRET2 biosensor assay can be adapted for high throughput screening of new HIV-1 PR inhibitors. It can be employed to screen for antiviral compounds that also target the proteases of other viruses.
has issue date	2005-06-13(xsd:dateTime)
bibo:doi	10.1016/j.jviromet.2005.04.012
bibo:pmid	15951029
has license	no-cc
sha1sum (hex)	f674866aa5bbc42a31e8b8f84e79ea98142a518e
schema:url	https://doi.org/10.1016/j.jviromet.2005.04.012
resource representing a document's title	A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer
has PubMed Central identifier	PMC7112859
has PubMed identifier	15951029
schema:publication	J Virol Methods
resource representing a document's body	covid:f674866aa5bbc42a31e8b8f84e79ea98142a518e#body_text
is schema:about of	named entity 'BIOLUMINESCENCE RESONANCE ENERGY TRANSFER' named entity 'blocked' named entity 'humanized' named entity 'generated' named entity 'biosensor' named entity 'manner' named entity 'site' named entity 'inhibitory' named entity 'Western blot' named entity 'confirmed' named entity 'advantages' covid:arg/f674866aa5bbc42a31e8b8f84e79ea98142a518e named entity 'INSERTED' named entity 'IS A' named entity 'MOLECULE' named entity 'REAL TIME' named entity 'MEASURES' named entity 'INCLUSION' named entity 'AFFECTED' named entity 'SAQUINAVIR' named entity 'WESTERN' named entity 'MAMMALIAN' named entity 'MODULATE' named entity 'LEVELS' named entity 'PROTEIN ' named entity 'HIGH THROUGHPUT SCREENING' named entity 'GAG-POL' named entity 'SUBSTRATE' named entity 'VIF' named entity 'CELLULAR' named entity 'STAUFEN' named entity 'GAG' named entity 'EXPRESSION' named entity 'ACTIVITY' named entity 'EXPRESSED' named entity 'INDICATING' named entity 'SMALL' named entity 'ACCUMULATION' named entity 'POWERFUL' named entity 'BRET' named entity 'SEA PANSY' named entity 'PROTEASE' named entity 'ADAPTED' named entity 'PROTEASES' named entity 'DOSE-DEPENDENT' named entity 'ASSAY' named entity 'DEFECTIVE' named entity 'MOLECULES' named entity 'STABLE' named entity 'OVEREXPRESSION' named entity 'REPORTER ASSAY' named entity 'ANTIVIRAL' named entity 'AUXILIARY' named entity 'ATTRACTIVE' named entity 'NEW' named entity 'TRBP' named entity 'PROTEASE' named entity 'ENERGY' named entity 'RNA' named entity 'HUMANIZED' named entity 'SIGNAL' named entity 'CODON' named entity 'COMPARTMENTS' named entity 'DESCRIBED' named entity 'PHENOMENON' named entity 'SIGNIFICANT' named entity 'USING' named entity 'BIOSENSOR' named entity 'HUMAN IMMUNODEFICIENCY VIRUS TYPE 1' named entity 'ASSAY' named entity 'TARGET' named entity 'SITE' named entity 'SENSITIVE' named entity 'VIRUSES' named entity 'LIVE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software